Upstream Bio, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Upstream Bio (NASDAQ: UPB) reported Q2 2026 results with cash and investments of $261.3M (56% of market cap) funding operations through 2027. The company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027 following completed FDA End-of-Phase 2 interactions. Completed enrollment in Phase 2 COPD trial (481 participants; data expected H2 2027) and reported positive Phase 2 data showing ~80% of patients achieved clinically meaningful nasal polyp improvements with quarterly dosing.
Why this rating
Meaningful clinical and regulatory progress (Phase 3 initiation imminent) in lead program; cash sufficient for trials; positive data support advancement. Significant relative to ~$468M market cap but clinical-stage risk remains high.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.